Tokyo, Japan, July 21, 2005 - (JCNN) - Mitsubishi Pharma (TSE: 4509) announced July 20 that its overseas subsidiary Mitsubishi Pharma Europe of London received approval to market argatroban, Mitsubishi Pharma's proprietary selective antithrombin agent, as of June 1 and put it on sale on July 15.
Mitsubishi Pharma Deutaschland is now marketing the agent under the trade name of Argatra in Germany.
Mitsubishi Pharma Europe plans to introduce the drug in Sweden, Holland, Austria, and Italy upon approval by authorities in respective countries.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group